Cardiologia Croatica, Vol. 6 No. 12, 2011.
Stručni rad
Extensive clinical experience with clopidogrel in the treatment of acute coronary syndrome
Darja Milovanovič Jarh
; Krka, d. d., Novo mesto, Slovenija
Breda Barbič-Žagar
orcid.org/0000-0002-1173-7361
; Krka, d. d., Novo mesto, Slovenija
Mateja Grošelj
; Krka, d. d., Novo mesto, Slovenija
Sažetak
Acute coronary syndrome (ACS) is a major problem for healthcare systems, as it is the cause of a large number of hospitalisations every year. Moreover, as ACS may be a life-threatening condition, timely decisions on pharmacological management as well as coronary revascularisation strategies are needed. Clopidogrel has a strong evidence base supporting its use as an effective and well tolerated antiplatelet agent for the secondary prevention of ischemic events in patients with various cardiovascular conditions, including those with ACS. An evidence base demonstrating the efficacy and safety of antiplatelet therapy has also been established for Zyllt® (Krka's clopidogrel) in many post-authorisation safety and efficacy studies. The studies yielded important results and an extensive data base, which is not available for any other generic clopidogrel. The high efficacy and good safety as well as the reasonable price of Krka’s clopidogrel could undoubtedly contribute to a better compliance with the treatment in more patients with ACS.
Ključne riječi
acute coronary syndrome; secondary prevention; clopidogrel
Hrčak ID:
74636
URI
Datum izdavanja:
15.11.2011.
Posjeta: 1.811 *